Abstract
Because its secretion is changed in cerebrospinal fluid and peripheral blood, the neuronal polypeptide VGF (nonacronymic) has been discussed as a biomarker for neuropsychiatric disorders. We have shown an enhanced VGF expression by T-cells from Alzheimer s disease (AD) patients. In this study, we investigated the VGF expression by peripheral monocytes in 38 AD patients, 5 patients with vascular dementia (VD), and 20 neuropsychiatrically healthy individuals using flow cytometry. We determined an enhanced number of VGF-expressing monocytes in VD patients compared to AD patients. VGF+CD14+ monocytes were not correlated with age, body mass index, Mini-Mental State Examination (MMSE), or Q albumin. These preliminary data support findings indicating that VGF might play a role as a peripheral biomarker in VD.
Author supplied keywords
Cite
CITATION STYLE
Busse, S., Meyer, E., Dobrowolny, H., Mawrin, C., Hartig, R., Bogerts, B., & Busse, M. (2022). VGF Expression by Monocytes in Patients with Alzheimer’s Disease and Vascular Dementia. GeroPsych: The Journal of Gerontopsychology and Geriatric Psychiatry, 35(3), 149–155. https://doi.org/10.1024/1662-9647/a000263
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.